<DOC>
	<DOCNO>NCT00117247</DOCNO>
	<brief_summary>The purpose study evaluate single dose pharmacokinetics ( PK ) subcutaneous ( SC ) darbepoetin alfa subject congestive heart failure ( CHF ) anemia .</brief_summary>
	<brief_title>A Study Repeat-Dose Subcutaneous Darbepoetin Alfa Subjects With Congestive Heart Failure Anemia , Single Dose Healthy Age- Sex-Matched Control Subjects</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Symptomatic CHF despite optimized therapy least previous 3 month ( treatment include diuretic , angiotensin convert enzyme [ ACE ] inhibitor , and/or A2 antagonist , unless tolerate ) Hemoglobin great equal 12.5 g/dL time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Heart Failure</keyword>
</DOC>